Day: January 30, 2023

Multi-Faceted Approach Accelerates Fortinet’s Global Commitment to Eliminate the Cybersecurity Skills Gap SUNNYVALE, Calif., Jan. 30, 2023 (GLOBE NEWSWIRE) — John Maddison, EVP of Products and CMO at Fortinet “Fortinet builds ML-driven automation into all of its SOC offerings to support short-staffed teams affected by the cybersecurity skills shortage. But technology alone won’t solve this […]

Multi-Faceted Approach Accelerates Fortinet’s Global Commitment to Eliminate the Cybersecurity Skills Gap SUNNYVALE, Calif., Jan. 30, 2023 (GLOBE NEWSWIRE) — John Maddison, EVP of Products and CMO at Fortinet “Fortinet builds ML-driven automation into all of its SOC offerings to support short-staffed teams affected by the cybersecurity skills shortage. But technology alone won’t solve this […]

One search, so many possibilities – cozycozy helps users find their perfect holiday accommodation from over 100+ booking platforms, including Airbnb. cozycozy Amalfi coast NEW YORK, Jan. 30, 2023 (GLOBE NEWSWIRE) — Cozycozy knows that finding the perfect place to stay can be hard. With the rise of so many vacation rental and hotel platforms […]

One search, so many possibilities – cozycozy helps users find their perfect holiday accommodation from over 100+ booking platforms, including Airbnb. cozycozy Amalfi coast NEW YORK, Jan. 30, 2023 (GLOBE NEWSWIRE) — Cozycozy knows that finding the perfect place to stay can be hard. With the rise of so many vacation rental and hotel platforms […]

SHANGHAI, China, Jan. 30, 2023 (GLOBE NEWSWIRE) — Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences”, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announced today that the National Medical Products Administration (the “NMPA”) has conducted urgent review and approval under Special Examination and Approval […]

SHANGHAI, China, Jan. 30, 2023 (GLOBE NEWSWIRE) — Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences”, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announced today that the National Medical Products Administration (the “NMPA”) has conducted urgent review and approval under Special Examination and Approval […]